Please login to the form below

Not currently logged in
Email:
Password:

belimumab

This page shows the latest belimumab news and features for those working in and with pharma, biotech and healthcare.

Is GSK planning to exit the respiratory business?

Is GSK planning to exit the respiratory business?

It is however growing at a much faster rate; respiratory grew 3%, HIV was up 11% and immuno-inflammation – led by lupus drug Benlysta (belimumab) – rose 28%.

Latest news

  • GSK closes in on EU approval for triple COPD therapy GSK closes in on EU approval for triple COPD therapy

    The CHMP also delivered more good news to GSK by recommending approval of the company's subcutaneous pen-injector of Benlysta (belimumab), providing a more patient-friendly alternative to the current

  • GSK and AZ drugs impress in lupus trials GSK and AZ drugs impress in lupus trials

    GSK reported new phase III data on a new subcutaneous formulation of its market-leading Benlysta (belimumab) product - which was approved as in one-hour infusion formulation for SLE in 2011, ... placebo. "On the basis of these data, we expect to progress

  • Hints of recovery at GSK as group sales climb Hints of recovery at GSK as group sales climb

    Some of its newer treatments have also failed to grow as expected, with the much-hyped lupus drug Benlysta (belimumab) - the first drug approved for the condition in fifty years - failing

  • GSK starts recovery from China crisis as growth returns GSK starts recovery from China crisis as growth returns

    Other gainers included platelet-booster Promacta (eltrombopag) - up 46 per cent to £186m in 2013 - and lupus treatment Benlysta (belimumab), which more than doubled to £146m.

  • 2013 - biotech boomed 2013 - biotech boomed

    to lupus treatment Benlysta (belimumab) and the late-stage type 2 diabetes candidate albiglutide.

More from news
Approximately 1 fully matching, plus 34 partially matching documents found.

Latest Intelligence

  • Opening up innovation Opening up innovation

    Leading this is Benlysta (belimumab), which in 2011 became the first new treatment for lupus to be approved in over 50 years and is being investigated for other auto antibody-dependent

  • Building a business that is lean and specialised Building a business that is lean and specialised

    The company was Human Genome Sciences and its acquirer, GlaxoSmithKline, had its eye on gaining full control of Benlysta (belimumab), the lupus product that the two had been co-marketing.

  • Pharma deals during July 2012 Pharma deals during July 2012

    These are Benlysta (belimumab), an antibody approved for the treatment of lupus; darapladib, a phase III small molecule drug for the treatment of cardiovascular disease; and albiglutide, an albumin-fusion protein

More from intelligence
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics